Key result
Cancer therapies are increasingly linked to RV dysfunction, requiring diagnostics like strain echocardiography and CMR.
Why the study?
The clinical impact and prognosis of right ventricular dysfunction in cancer patients receiving cardiotoxic therapies remain unclear and require further investigation.
What is the role and clinical impact of right ventricular dysfunction in cardiotoxicity caused by cancer therapies?
What is the role and clinical impact of right ventricular dysfunction in cardiotoxicity caused by cancer therapies?
This review highlights the emerging recognition of right ventricular dysfunction as an important factor in cancer therapy-induced cardiotoxicity.
Alerts clinicians to monitor RV function during cancer therapy; leaves open prospective validation of strain and CMR for routine use.
Right ventricular dysfunction (RVD) is present in several clinical conditions, and its clinical impact and prognosis in cardiology has been more studied in recent years. In oncology, some studies have tried to determine the role of RVD in cardiotoxicity caused by some therapies including anthracyclines, trastuzumab, cyclophosphamide and dasatinib. In the present study, we made a literature review on the subject, trying to highlight the challenges for the coming years.
No takes yet. Share an insight, caveat, or question.
Bond et al. (2022) conducted a review in Right ventricular dysfunction in cancer patients. Cancer therapies (anthracyclines, trastuzumab, cyclophosphamide, dasatinib) was evaluated. Right ventricular dysfunction is an increasingly recognized complication of cancer therapies, highlighting the need for validated diagnostic methods like strain echocardiography and cardiac magnetic resonance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: